Skip to main content

MaxCyte, Inc. (MXCT) Stock Forecast

Data as of May 2, 2026

Healthcare · Current price $0.88 (+0.01%)

Consensus Target
$6.00
Upside
+581.7%
Analysts
1
Rating
Buy(2.00)

Price Target Range

Low $6.00High $6.00

Consensus Price Target Over Time

Analyst Rating Distribution

Last 3 Months

Consensus
Buy
Strong Buy0
Buy1
Hold0
Sell0
Strong Sell0

6-Month Trend

Latest Analyst Forecasts

Price targets issued by Wall Street analysts. Upside calculated against today's price.

DateAnalystFirmPrice TargetUpside
Mar 12, 2025Mark MassaroBTIG$6.00+581.7%
Mar 13, 2024Mark MassaroBTIG$8.00+809.0%
Aug 14, 2022Mark MassaroBTIG$11.00+1149.9%

MXCT vs Sector & Market

MetricMXCTHealthcare AvgLarge Cap Avg
Analyst Rating2.002.242.41
Analyst Count1818
Target Upside+581.7%+1149.5%+14.9%
P/E Ratio-2.096.8731.19

Revenue Estimates

PeriodLowAvgHigh#
2026-12-31$31M$31M$31M5
2027-12-31$36M$37M$39M5
2028-12-31$38M$39M$40M2
2029-12-31$79M$82M$84M1

EPS Estimates

PeriodLowAvgHigh#
2026-12-31$-0.26$-0.26$-0.263
2027-12-31$-0.26$-0.25$-0.243
2028-12-31$-0.25$-0.24$-0.231
2029-12-31$-0.11$-0.11$-0.111

Frequently Asked Questions

What is the analyst consensus for MXCT?

The consensus among 1 analysts covering MaxCyte, Inc. (MXCT) is Buy with an average price target of $6.00.

What is the highest price target for MXCT?

The highest price target for MXCT is $11.00, set by Mark Massaro at BTIG on 2022-08-14.

What is the lowest price target for MXCT?

The lowest price target for MXCT is $6.00, set by Mark Massaro at BTIG on 2025-03-12.

How many analysts cover MXCT?

1 analysts have issued ratings for MaxCyte, Inc. in the past 12 months.

Is MXCT a buy or sell right now?

Based on 1 analyst ratings, MXCT has a consensus rating of Buy (2.00/5) with a +581.7% upside to the consensus target of $6.00.

What are the earnings estimates for MXCT?

Analysts estimate MXCT will report EPS of $-0.26 for the period ending 2026-12-31, with revenue estimated at $31M.

Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.